Swiss National Bank’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Swiss National Bank’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-185,200	Closed	-$24.4M	–	2419
2025 Q1	$24.4M	Sell	185,200 -1,800	-1%	-$224K	0.02%	573
2024 Q4	$15.6M	Buy	187,000 +1,500	+0.8%	+$123K	0.01%	735
2024 Q3	$13.6M	Buy	185,500 +13,900	+8%	+$1.04M	0.01%	787
2024 Q2	$11.8M	Buy	171,600 +700	+0.4%	+$48.5K	0.01%	822
2024 Q1	$11.8M	Buy	170,900 +500	+0.3%	+$34.4K	0.01%	841
2023 Q4	$12.2M	Sell	170,400 -19,400	-10%	-$1.12M	0.01%	799
2023 Q3	$9.89M	Buy	189,800 +3,100	+2%	+$181K	0.01%	893
2023 Q2	$11.8M	Buy	186,700 +2,800	+2%	+$174K	0.01%	822
2023 Q1	$9.96M	Sell	183,900 -21,300	-10%	-$1.03M	0.01%	867
2022 Q4	$10.9M	Buy	205,200 +3,900	+2%	+$195K	0.01%	872
2022 Q3	$9.37M	Buy	201,300 +5,500	+3%	+$287K	0.01%	913
2022 Q2	$11.2M	Buy	195,800 +2,200	+1%	+$125K	0.01%	854
2022 Q1	$11.8M	Buy	193,600 +41,500	+27%	+$2.16M	0.01%	916
2021 Q4	$7.96M	Sell	152,100 -400	-0.3%	-$16.8K	﹤0.01%	1151
2021 Q3	$5.68M	Buy	152,500 +900	+0.6%	+$31.3K	﹤0.01%	1371
2021 Q2	$6.19M	Sell	151,600 -13,200	-8%	-$488K	﹤0.01%	1341
2021 Q1	$5.59M	Buy	164,800 +3,700	+2%	+$128K	﹤0.01%	1385
2020 Q4	$5.12M	Hold	161,100	–	–	﹤0.01%	1364
2020 Q3	$4.13M	Buy	161,100 +27,000	+20%	+$616K	﹤0.01%	1292
2020 Q2	$3.44M	Buy	134,100 +20,200	+18%	+$409K	﹤0.01%	1375
2020 Q1	$1.75M	Buy	113,900 +24,200	+27%	+$526K	﹤0.01%	1530
2019 Q4	$3.08M	Buy	89,700 +2,800	+3%	+$33.6K	﹤0.01%	1474
2019 Q3	$649K	Hold	86,900	–	–	﹤0.01%	2268
2019 Q2	$1.13M	Buy	86,900 +7,100	+9%	+$91.1K	﹤0.01%	2053
2019 Q1	$972K	Buy	79,800 +2,400	+3%	+$30.7K	﹤0.01%	2074
2018 Q4	$882K	Buy	77,400 +3,100	+4%	+$50K	﹤0.01%	2074
2018 Q3	$1.61M	Hold	74,300	–	–	﹤0.01%	1850
2018 Q2	$1.31M	Hold	74,300	–	–	﹤0.01%	1997
2018 Q1	$1.56M	Buy	74,300 +4,500	+6%	+$87.7K	﹤0.01%	1796
2017 Q4	$1.01M	Hold	69,800	–	–	﹤0.01%	2094
2017 Q3	$1.1M	Buy	69,800 +16,500	+31%	+$242K	﹤0.01%	2000
2017 Q2	$662K	Hold	53,300	–	–	﹤0.01%	2308
2017 Q1	$866K	Hold	53,300	–	–	﹤0.01%	2119
2016 Q4	$804K	Hold	53,300	–	–	﹤0.01%	2167
2016 Q3	$812K	Sell	53,300 -1,400	-3%	-$56.6K	﹤0.01%	2105
2016 Q2	$2.12M	Hold	54,700	–	–	﹤0.01%	1464
2016 Q1	$1.47M	Buy	54,700 +14,800	+37%	+$493K	﹤0.01%	1641
2015 Q4	$2.15M	Hold	39,900	–	–	0.01%	1291
2015 Q3	$1.6M	Buy	39,900 +15,600	+64%	+$509K	﹤0.01%	1452
2015 Q2	$776K	Hold	24,300	–	–	﹤0.01%	1954
2015 Q1	$580K	Buy	24,300 +7,300	+43%	+$164K	﹤0.01%	2095
2014 Q4	$300K	Hold	17,000	–	–	﹤0.01%	2401
2014 Q3	$233K	Hold	17,000	–	–	﹤0.01%	2403
2014 Q2	$287K	Buy	+17,000	New	+$281K	﹤0.01%	2402

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Swiss National Bank's ITCI Position: Q2 2025 in Review

Swiss National Bank sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 185,200 shares — an estimated $24.4M sold.

Swiss National Bank first reported a position in ITCI in Q2 2014 and held it in 44 quarters. The position peaked at $24.4M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Swiss National Bank reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Swiss National Bank sold 185,200 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $24.4M.
Swiss National Bank first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 44 quarters.
Swiss National Bank's Intra-Cellular Therapies Inc. position peaked at $24.4M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Swiss National Bank's 13F filing for Q2 2025, filed 12 Aug 2025.